Bernard A. Fox, Co – founder, President, and CEO of UbiVac, shared a post on LinkedIn:
“Another great day for me! I visited Kelonia Therapeutics in Boston.
Very proud of Dr. Kevin Friedman and all he has accomplished as Founder and CEO at Kelonia Therapeutics . An alumni of the PHD program in my Lab at the Earle A. Chiles Research Institute / Providence Cancer Institute / OHSU MMI / FoxLab & the fellowship program at the SurgeryBranch, National Cancer Institute (NCI) – he and his team are well on their way to democratizing CAR T cell therapy by developing an off-the-shelf cancer therapy that engineers T cells in the body to destroy cancer cells – and doesn’t require chemotherapy.
From my perspective – a great example of the important role the NCI has played in the development of investigators that think differently and work hard to move High risk / high reward projects into humans with cancer.
We need more of this!
Patients need more of this.”
Other articles featuring Bernard A. Fox on OncoDaily.